Clinic Roundup
Santarus Inc., of San Diego, said analysis of top-line safety data from a 12-month extended-use study in patients treated daily with either budesonide MMX 6 mg or placebo showed a similar frequency of treatment-related adverse events for both groups (21 percent to 21.3 percent) and no clinically meaningful differences in the numbers of patients with abnormal bone mineral density scans at baseline and end of the study between the budesonide and placebo groups.
To continue reading subscribe now to BioWorld Today
Learn More about BioWorld Today
Already a subscriber? Sign In or Buy now to activate your subscription
Note: our contact information has changed
Customer Care: http://support.clarivate.com
© 2018 Clarivate Analytics.
Reproduction, reposting content is strictly prohibited.
Reproduction, reposting content is strictly prohibited.